Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A study including researchers in Nuffield Department of Population Health has found that government investment in healthcare research is good for the wider economy.

The research, supported by the NIHR Oxford Biomedical Research Centre (BRC), found that the return on investment in the Oxford BRC was 46% in terms of income and job creation alone.

The paper, ‘A macroeconomic assessment of the impact of medical research expenditure: A case study of NIHR Biomedical Research Centres’, was published in the Plos One journal.

There are a number of methodologies for measuring research impact; one that has been widely used is the Payback Framework, which aims to capture the full life-cycle of biomedical research, from the initial concept to the eventual health, economic and societal benefits.

However, finding the data this framework requires over lengthy time lags is a major difficulty and, conscious that health benefits may not be realised for several years, the Oxford researchers decided to focus on the shorter-term economic returns by using an input-output analysis framework, which is often used to assess the impact of major government spending projects on other aspects of regional economies.

Read more (NIHR Oxford Biomedical Research Centre website)

Similar stories

Major grant to strengthen research and benefit patients

Oxford University Hospitals (OUH) has made a grant of £11.5 million to the University of Oxford, which the University will match with other funding, to allow the development of major clinical research facilities which have the potential to support the introduction of innovative and ground-breaking treatments for patients.

Dr Lennard Lee awarded ACP McElwain Prize for contributions to medical oncology

Dr Lee (Department of Oncology) received the award to acknowledge his contributions during the COVID-19 pandemic, through the establishment of the UK Coronavirus Cancer Monitoring Project.

Oxford joins forces with 11 universities to launch social impact investment fund

The University of Oxford has joined forces with 11 leading universities to create Impact 12, an impact investment fund to support mission-led university ventures.

Ivermectin to be investigated as a possible treatment for COVID-19 in the PRINCIPLE trial

From today, ivermectin is being investigated in the UK as part of the Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses (PRINCIPLE), the world’s largest clinical trial of possible COVID-19 treatments for recovery at home and in other non-hospital settings.

Potential for radiotherapy and VTP multimodality therapy for prostate cancer

A recent collaborative study from the University of Oxford has investigated the potential benefit of a combined therapy approach to prostate cancer treatment, using radiotherapy and vascular targeted photodynamic therapy (VTP), which could lead to first-in-man early phase clinical trials.

Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study

A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.